Cancer in Hungary

Built partly from other countries' data. IARC's method code for Hungary's incidence estimate is 3b: national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data). Read the figures as a regional estimate, not a count.

• Incidence: method 3b, national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data).
• Mortality: method 1, trends in national rates projected to 2024.
• Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Hungary”, in Eastern Europe (Europe), Very High HDI, high income.
• Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Hungary, captured 2026-10-07 to 2026-10-08. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Hungary is open is on the registry page, under Contacts and Locations.

Hungary is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.